Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy

Inclusion Criteria: * Informed consent form signed prior to study entry * Age between 18-69 years old * Pathology approved to be nasopharyngeal carcinoma (types WHO Ⅱ-Ⅲ) * Stage Ⅲ, Ⅳa, Ⅳb according to UICC (International Union Against Cancer) 2002 6th edition criteria * Primary tumor measurable * KPS score ≥80 * Expected life span ≥6 months * Adequate bone marrow function: White Blood Cell≥4×109/L，Hemoglobin≥100g/L，Platelet≥100×109/L * Adequate liver function: ALAT/ASAT\<1.5 × upper limit of normal (ULN), bilirubin \<1.5×ULN * Adequate renal function: Creatinine Clearance \< 1.5×ULN Exclusion Criteria: * Evidence of distant metastatic disease * Surgical procedure of the primary tumor or lymph nodes (except diagnostic biopsy) * Previous radiotherapy for the primary tumor or lymph nodes * Previous exposure to epidermal growth factor-targeted therapy * Prior chemotherapy or immunotherapy for the primary tumor * Other previous malignancy within 5 years, except non-melanoma skin cancer or pre-invasive carcinoma of the cervix * Any investigational agent prior to the 1st study medication * Participation in another clinical study within the 30 days prior to Inclusion in this study. * Peripheral neuropathy \> grade 1 * Known grade 3 or 4 allergic reaction to any of the study treatment * History of severe pulmonary or cardiac disease * Creatinine Clearance \< 30ml/min * Know drug abuse / alcohol abuse * Legal incapacity or limited legal capacity * Active systemic infection * Medical or psychiatric illness, which in the investigators' opinions, would not permit the subject to complete or fully and completely understand the risks and potential complications of the study * Concurrent chronic systemic immune therapy or hormone therapy not indicated in the study protocol * Pregnancy (confirmed by serum or urine β-HCG) or lactation period * Severe intercurrent illness, e.g. uncontrolled hypertension, cardiac failure